Search research articles
Contact Us
Filters
Showing results (191-200 of 206) with videos related to
Page
of 21
Sort By:
British Journal of Cancer
|
July 10, 2019
Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
Eiji Oki, Yasunori Emi, Takeharu Yamanaka, et al.
Cancer Science
|
May 15, 2023
Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1, an ancillary of JCOG0910
Dai Shida, Aya Kuchiba, Tatsuhiro Shibata, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
November 22, 2019
[Clinical Utility of Comprehensive Genome Profiling Using FoundationOne CDx in Japanese Population(PROFILE-F Study)]
Yuichi Kumaki, Kenta Takahashi, Takahiro Mitsumura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2016
12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study
Takeharu Yamanaka, Eiji Oki, Kentaro Yamazaki, et al.
Biochemical and Biophysical Research Communications
|
April 22, 2018
Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types
Toshiyuki Ishiba, Andreas-Claudius Hoffmann, Joshua Usher, et al.
Langenbeck'S Archives of Surgery
|
February 25, 2022
A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study
Masaru Matsumura, Kiyoshi Hasegawa, Masaru Oba, et al.
International Journal of Clinical Oncology
|
July 21, 2022
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
Takahiko Ito, Atsuo Takashima, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology
|
March 4, 2026
Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
Ryosuke Kawagoe, Toshikazu Moriwaki, Kentaro Yamazaki, et al.
Genome Medicine
|
December 24, 2016
Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine
Masayuki Nagahashi, Toshifumi Wakai, Yoshifumi Shimada, et al.
Chinese Journal of Cancer
|
December 24, 2016
Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
Masahito Kotaka, Ruihua Xu, Kei Muro, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 206) with videos related to
Sort By:
Page
of 21
British Journal of Cancer
|
July 10, 2019
Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
Eiji Oki, Yasunori Emi, Takeharu Yamanaka, et al.
Cancer Science
|
May 15, 2023
Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1, an ancillary of JCOG0910
Dai Shida, Aya Kuchiba, Tatsuhiro Shibata, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
November 22, 2019
[Clinical Utility of Comprehensive Genome Profiling Using FoundationOne CDx in Japanese Population(PROFILE-F Study)]
Yuichi Kumaki, Kenta Takahashi, Takahiro Mitsumura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2016
12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study
Takeharu Yamanaka, Eiji Oki, Kentaro Yamazaki, et al.
Biochemical and Biophysical Research Communications
|
April 22, 2018
Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types
Toshiyuki Ishiba, Andreas-Claudius Hoffmann, Joshua Usher, et al.
Langenbeck'S Archives of Surgery
|
February 25, 2022
A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study
Masaru Matsumura, Kiyoshi Hasegawa, Masaru Oba, et al.
International Journal of Clinical Oncology
|
July 21, 2022
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
Takahiko Ito, Atsuo Takashima, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology
|
March 4, 2026
Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
Ryosuke Kawagoe, Toshikazu Moriwaki, Kentaro Yamazaki, et al.
Genome Medicine
|
December 24, 2016
Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine
Masayuki Nagahashi, Toshifumi Wakai, Yoshifumi Shimada, et al.
Chinese Journal of Cancer
|
December 24, 2016
Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
Masahito Kotaka, Ruihua Xu, Kei Muro, et al.
Page
of 21